Welcome to LookChem.com Sign In|Join Free

CAS

  • or

476-32-4

Post Buying Request

476-32-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

476-32-4 Usage

Description

Chelidonine, also known as ranunculine, is a benzophenanthridine alkaloid isolated from the whole plant of Chelidonium majus. It has been used as a painkiller in clinical treatment based on its morphine-like analgesic effect. Pharmacological research has demonstrated that chelidonine has antitumor, antibacterial, and spasmolysis activities. It is a major bioactive isoquinoline alkaloid ingredient in Chelidonium majus and can induce apoptosis in some transformed or malignant cell lines.

Uses

Used in Pharmaceutical Industry:
Chelidonine is used as a painkiller for its morphine-like analgesic effect.
Used in Traditional Chinese Medicine:
Chelidonine is used for the treatment of jaundice, biliary colic, cholelithiasis, cutaneous tuberculosis, and other diseases, including anti-inflammatory, analgesia, relieving cough, inducing diuresis, anticancer, antifungal, relieving asthma, and detoxification.
Used in Antitumor Applications:
Chelidonine is used as an antitumor agent, inducing Bcl-2and caspase-dependent apoptosis in HepG2 human liver carcinoma cells and Jurkat human T cells.
Used in Alkaloid Research:
Chelidonine is used as a major effective ingredient in the study of benzophenanthridine alkaloids and their biosynthetic pathways.
Used in Poison:
Chelidonine can be used as a poison, acting as a central nervous system depressant causing sleepiness, depression, slowing of the pulse, coma, and circulatory failure. However, this use is not recommended due to its harmful effects.

Pharmacological action

Chelidonine is an isolate of Papaveraceae with acetylcholinesterase and butyrylcholinesterase (a nonspecific cholinesterase) inhibitory activity. AChE (acetylcholinesterase) inhibitors or anti-cholinesterases inhibit the cholinesterase enzyme from breaking down ACh, increasing both the level and duration of the neurotransmitter action. According to the mode of action, AChE inhibitors can be divided into two groups: irreversible and reversible. Reversible inhibitors, competitive or noncompetitive, mostly have therapeutic applications, while toxic effects are associated with irreversible AChE activity modulators. Reversible AChE inhibitors play an important role in pharmacological manipulation of the enzyme activity. These inhibitors include compounds with different functional groups (carbamate, quaternary or tertiary ammonium group), and have been applied in the diagnostic and/or treatment of various diseases such as: myasthenia gravis, AD, post-operative ileus, bladder distention, glaucoma, as well as antidote to anticholinergic overdose. In general, methyltransferases of BIA metabolism accept a wide variety of alkaloid substrates with diverse backbone structures, with some showing more flexibility than others with respect to substrate range.

History

Chelidonine was isolated from Chelidonium majus. L in 1824 for the first time. Pharmacological studies found that it exerted antitumor effect via different mechanisms. However, its poor bioavailability limited its application. Some researchers developed a chelidonine/polylactic acid copolymer nanoparticle using nanotechnology. The nano-chelidonine showed good tissue distribution without causing any toxicity in mice and could enter into the brain tissues, showing great application potential. In addition, nano-chelidonine showed protective effect on liver injury induced by cadmium in mice .In 1981, an Austrian researcher isolated a novel compound ukrain (phosphorothioate derivative of chelidonine) from Chelidonium majus. L. Ukrain could inhibit tumor cell proliferation through a variety of mechanisms. Currently, ukrain is used as an antitumor drug for the clinical treatment of lung cancer, breast cancer, prostate cancer, and pancreatic cancer . In 2004, quarter amine chelidonine phosphorothioate derivatives have been applied for an invention patent as anticancer drugs in China.Chelidonine has morphine-like analgesic effects suggesting that its analgesic effect is mainly peripheral and cannot be antagonized by the morphine receptor antagonist naloxone . The 6-alkoxy and 6-acyloxy derivatives of chelidonine can inhibit the central nervous system, especially for nerve terminal, and show sedative and hypnotic effects .

Biochem/physiol Actions

Inhibits tubulin polymerisation (IC50=24 μM), thereby disrupting microtubule structure in cells and inducing a G2/M mitotic arrest.

Pharmacology

Chelidonine has a variety of pharmacological effects, mainly manifested in the following aspects:1. The effect on nervous system (analgesia, sedation)Chelidonine, as a protopine, has analgesia effect similar to that of morphine. After intragastric administration (5–20 mg/kg) to mice, it showed a dose-dependent analgesic effect, which could sustain 4–48 h . Chelidonine derivatives also have sedative and hypnotic effects .2. The effect on cardiovascular systemChelidonine has many effects on cardiovascular system, including exciting heart, expanding coronary blood vessels, and increasing blood pressure. Chelidonine (0.01–0.02 mg) leads to the excitement of frog heart in vitro, as well as slowdown of heart beat. Higher dosage (0.05 mg) of chelidonine could cause arrhythmia and diastolic cardiac arrest .3. The antitumor effectChelidonine is a toxic substance that can influence mitosis. In vitro studies have shown that chelidonine had significant inhibitory effects for gastric cancer, leukemia, nasopharyngeal carcinoma, and hepatoma carcinoma cells. It also could delay the growth of malignant tumors. Its antitumor effects were mediated by different mechanisms, which still need further studies .4. The effect on smooth muscleChelidonine has spasmolytic and diastolic effects and can inhibit a variety of smooth muscle spasm. Obvious spasmolytic effects for gastrointestinal tract and bronchial and urinary system have been reported .5. The antibacterial effectChelidonine has antibacterial effect. It inhibits Mycobacterium tuberculosis in vivo and inhibits alpha Streptococcus, Diplococcus pneumoniae, and other gram-positive bacteria in vitro. In addition, chelidonine also shows inhibitory effect on Kauffman-Wolf Trichophyta and Epidermophyton floccosum .6. Other pharmacological effectsChelidonine showed protective effects on cadmium chloride-induced liver and kidney toxicity in rats. Chelidonine can inhibit the growth of human keratinocytes. Guinea pig test confirmed that chelidonine (4–10 mg/kg) could prevent or delay the anaphylactic shock. In addition, chelidonine has anti-mite effect and good synergistic effect with trichlorfon or omethoate to prevent cotton bollworm.

Clinical Use

Chelidonine has been used as a painkiller in clinical application due to its significant analgesic effect. Chelidonine phosphate can be used for treatment of gastrointestinal and ulcer pain, as a substitute of morphine preparations. Wei Tong Shu capsule is used to treat pain caused by gastric convulsion, chronic gastritis, gastric ulcer, and duodenal ulcer. Its main effective compositions are chelidonine and protopine. Fu Fang Zhong Yao Tong An injection has collateral dredging and analgesic effects and can be used for the treatment of moderate pain caused by chemoradiotherapy or non-chemoradiotherapy of gastric cancer, lung cancer, and liver cancer. Its two main components are chelidonine and sinomenine. Ukrain (NSC-631570), a phosphorothioate derivative of chelidonine, has been used in clinical treatment as an effective antitumor drug for the treatment of lung cancer, breast cancer, prostate cancer, and pancreatic cancer.

Check Digit Verification of cas no

The CAS Registry Mumber 476-32-4 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 4,7 and 6 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 476-32:
(5*4)+(4*7)+(3*6)+(2*3)+(1*2)=74
74 % 10 = 4
So 476-32-4 is a valid CAS Registry Number.
InChI:InChI=1/C20H19NO5/c1-21-7-13-11(2-3-15-20(13)26-9-23-15)18-14(22)4-10-5-16-17(25-8-24-16)6-12(10)19(18)21/h2-3,5-6,14,18-19,22H,4,7-9H2,1H3/t14-,18-,19+/m0/s1

476-32-4Synthetic route

C27H21NO7
1032645-05-8

C27H21NO7

chelidonine
476-32-4

chelidonine

Conditions
ConditionsYield
With lithium aluminium tetrahydride In 1,4-dioxane at 20℃; for 19h; Reflux; Inert atmosphere;88%
methyl (5bR,5cR,6aS,11bS)-5b,6a,11b,13-tetrahydro-[1,3]dioxolo[4',5':4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]oxireno[2,3-a]phenanthridine-12(5cH)-carboxylate

methyl (5bR,5cR,6aS,11bS)-5b,6a,11b,13-tetrahydro-[1,3]dioxolo[4',5':4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]oxireno[2,3-a]phenanthridine-12(5cH)-carboxylate

chelidonine
476-32-4

chelidonine

Conditions
ConditionsYield
With lithium aluminium tetrahydride In tetrahydrofuran; 1,4-dioxane for 17h; Reflux;82%
ethanol
64-17-5

ethanol

(+)-Didehydrochelidonin
24181-71-3

(+)-Didehydrochelidonin

NaBH4

NaBH4

chelidonine
476-32-4

chelidonine

(-)-5-methyl-2,3:7,8-bis(methylenedioxy)-10b-triethylsilyloxy-4b,10b,11,12-tetrahydrobenzo[c]phenanthridin-6(5H)-one
1337985-26-8

(-)-5-methyl-2,3:7,8-bis(methylenedioxy)-10b-triethylsilyloxy-4b,10b,11,12-tetrahydrobenzo[c]phenanthridin-6(5H)-one

chelidonine
476-32-4

chelidonine

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1.1: potassium carbonate; 2,3-dicyano-5,6-dichloro-p-benzoquinone / benzene / 7 h / 85 °C / Inert atmosphere
2.1: dichloromethane / 27 h / 0 - 20 °C / Inert atmosphere
3.1: water; sodium hydroxide / tetrahydrofuran / 16 h / 20 - 40 °C
4.1: toluene-4-sulfonic acid / methanol / 6 h / 20 °C / Inert atmosphere
4.2: 2 h / 0 °C / Inert atmosphere
5.1: 1,8-diazabicyclo[5.4.0]undec-7-ene / N,N-dimethyl-formamide / 48 h / 110 °C
6.1: lithium aluminium tetrahydride / diethyl ether / 1 h / 50 °C / Inert atmosphere
7.1: platinum(IV) oxide; hydrogen / ethanol / 14 h / 20 °C / 760.05 Torr
8.1: triethylsilane; boron trifluoride diethyl etherate / dichloromethane / 22 h / 50 °C / Inert atmosphere
View Scheme
(-)-5-methyl-2,3:7,8-bis(methylenedioxy)-10b-triethylsilyloxy-4b,10b-dihydrobenzo[c]phenanthridin-6(5H)-one
1337985-30-4

(-)-5-methyl-2,3:7,8-bis(methylenedioxy)-10b-triethylsilyloxy-4b,10b-dihydrobenzo[c]phenanthridin-6(5H)-one

chelidonine
476-32-4

chelidonine

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1.1: dichloromethane / 27 h / 0 - 20 °C / Inert atmosphere
2.1: water; sodium hydroxide / tetrahydrofuran / 16 h / 20 - 40 °C
3.1: toluene-4-sulfonic acid / methanol / 6 h / 20 °C / Inert atmosphere
3.2: 2 h / 0 °C / Inert atmosphere
4.1: 1,8-diazabicyclo[5.4.0]undec-7-ene / N,N-dimethyl-formamide / 48 h / 110 °C
5.1: lithium aluminium tetrahydride / diethyl ether / 1 h / 50 °C / Inert atmosphere
6.1: platinum(IV) oxide; hydrogen / ethanol / 14 h / 20 °C / 760.05 Torr
7.1: triethylsilane; boron trifluoride diethyl etherate / dichloromethane / 22 h / 50 °C / Inert atmosphere
View Scheme
(-)-12-(3-chlorobenzoyloxy)-11-hydroxy-5-methyl-2,3:7,8-bis(methylenedioxy)-10b-triethylsilyloxy-4b,5,6,10b,11,12-hexahydrobenzo[c]phenanthridin-6(5H)-one
1337985-33-7

(-)-12-(3-chlorobenzoyloxy)-11-hydroxy-5-methyl-2,3:7,8-bis(methylenedioxy)-10b-triethylsilyloxy-4b,5,6,10b,11,12-hexahydrobenzo[c]phenanthridin-6(5H)-one

chelidonine
476-32-4

chelidonine

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1.1: water; sodium hydroxide / tetrahydrofuran / 16 h / 20 - 40 °C
2.1: toluene-4-sulfonic acid / methanol / 6 h / 20 °C / Inert atmosphere
2.2: 2 h / 0 °C / Inert atmosphere
3.1: 1,8-diazabicyclo[5.4.0]undec-7-ene / N,N-dimethyl-formamide / 48 h / 110 °C
4.1: lithium aluminium tetrahydride / diethyl ether / 1 h / 50 °C / Inert atmosphere
5.1: platinum(IV) oxide; hydrogen / ethanol / 14 h / 20 °C / 760.05 Torr
6.1: triethylsilane; boron trifluoride diethyl etherate / dichloromethane / 22 h / 50 °C / Inert atmosphere
View Scheme
C22H19NO6

C22H19NO6

chelidonine
476-32-4

chelidonine

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1: sodium tetrahydroborate; methanol / 0.5 h / 0 °C
2: potassium hydroxide / 2 h / 0 - 20 °C
3: triphenylphosphine; carbon tetrabromide / dichloromethane / 0.5 h / 0 - 20 °C
4: sodium hydride / N,N-dimethyl-formamide; mineral oil / 3 h / 0 - 20 °C
5: tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidine][benzylidene]ruthenium(II) dichloride / toluene / 1 h / 70 °C / Inert atmosphere
6: N-Bromosuccinimide; water / tetrahydrofuran / 1.5 h / 20 °C
7: potassium tert-butylate / tetrahydrofuran / 0.75 h / -78 °C
8: lithium aluminium tetrahydride / tetrahydrofuran; 1,4-dioxane / 17 h / Reflux
View Scheme
methyl ((1S,2R)-2-(4-(hydroxymethyl)benzo[d][1,3]dioxol-5-yl)-1-(6-vinylbenzo[d][1,3]dioxol-5-yl)but-3-en-1-yl)carbamate

methyl ((1S,2R)-2-(4-(hydroxymethyl)benzo[d][1,3]dioxol-5-yl)-1-(6-vinylbenzo[d][1,3]dioxol-5-yl)but-3-en-1-yl)carbamate

chelidonine
476-32-4

chelidonine

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: triphenylphosphine; carbon tetrabromide / dichloromethane / 0.5 h / 0 - 20 °C
2: sodium hydride / N,N-dimethyl-formamide; mineral oil / 3 h / 0 - 20 °C
3: tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidine][benzylidene]ruthenium(II) dichloride / toluene / 1 h / 70 °C / Inert atmosphere
4: N-Bromosuccinimide; water / tetrahydrofuran / 1.5 h / 20 °C
5: potassium tert-butylate / tetrahydrofuran / 0.75 h / -78 °C
6: lithium aluminium tetrahydride / tetrahydrofuran; 1,4-dioxane / 17 h / Reflux
View Scheme
methyl (6R,7S)-6-vinyl-7-(6-vinylbenzo[d][1,3]dioxol-5-yl)-6,9-dihydro-[1,3]dioxolo[4,5-h]isoquinoline-8(7H)-carboxylate

methyl (6R,7S)-6-vinyl-7-(6-vinylbenzo[d][1,3]dioxol-5-yl)-6,9-dihydro-[1,3]dioxolo[4,5-h]isoquinoline-8(7H)-carboxylate

chelidonine
476-32-4

chelidonine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidine][benzylidene]ruthenium(II) dichloride / toluene / 1 h / 70 °C / Inert atmosphere
2: N-Bromosuccinimide; water / tetrahydrofuran / 1.5 h / 20 °C
3: potassium tert-butylate / tetrahydrofuran / 0.75 h / -78 °C
4: lithium aluminium tetrahydride / tetrahydrofuran; 1,4-dioxane / 17 h / Reflux
View Scheme
methyl (5bR,12bS)-5b,14-dihydro-[1,3]dioxolo[4',5':4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridine-13(12bH)-carboxylate

methyl (5bR,12bS)-5b,14-dihydro-[1,3]dioxolo[4',5':4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridine-13(12bH)-carboxylate

chelidonine
476-32-4

chelidonine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: N-Bromosuccinimide; water / tetrahydrofuran / 1.5 h / 20 °C
2: potassium tert-butylate / tetrahydrofuran / 0.75 h / -78 °C
3: lithium aluminium tetrahydride / tetrahydrofuran; 1,4-dioxane / 17 h / Reflux
View Scheme
methyl (5bR,6S,7S,12bS)-6-bromo-7-hydroxy-5b,7,12b,14-tetrahydro-[1,3]dioxolo[4',5':4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridine-13(6H)-carboxylate

methyl (5bR,6S,7S,12bS)-6-bromo-7-hydroxy-5b,7,12b,14-tetrahydro-[1,3]dioxolo[4',5':4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridine-13(6H)-carboxylate

chelidonine
476-32-4

chelidonine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: potassium tert-butylate / tetrahydrofuran / 0.75 h / -78 °C
2: lithium aluminium tetrahydride / tetrahydrofuran; 1,4-dioxane / 17 h / Reflux
View Scheme
C23H22BrNO6

C23H22BrNO6

chelidonine
476-32-4

chelidonine

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: sodium hydride / N,N-dimethyl-formamide; mineral oil / 3 h / 0 - 20 °C
2: tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidine][benzylidene]ruthenium(II) dichloride / toluene / 1 h / 70 °C / Inert atmosphere
3: N-Bromosuccinimide; water / tetrahydrofuran / 1.5 h / 20 °C
4: potassium tert-butylate / tetrahydrofuran / 0.75 h / -78 °C
5: lithium aluminium tetrahydride / tetrahydrofuran; 1,4-dioxane / 17 h / Reflux
View Scheme
N-t-butyloxycarbonyl-DL-alanine
3744-87-4, 7764-95-6, 15761-38-3

N-t-butyloxycarbonyl-DL-alanine

chelidonine
476-32-4

chelidonine

O-(N-tert-butoxycarbonyl-alanyl) chelidonine

O-(N-tert-butoxycarbonyl-alanyl) chelidonine

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃;95.4%
isatoic anhydride
118-48-9

isatoic anhydride

chelidonine
476-32-4

chelidonine

C27H24N2O6

C27H24N2O6

Conditions
ConditionsYield
With dmap In N,N-dimethyl-formamide at 60℃; for 7h;95.1%
chelidonine
476-32-4

chelidonine

A

(+)-chelidonine N-oxide
76786-86-2, 98302-76-2, 98302-77-3

(+)-chelidonine N-oxide

B

(+)-chelidonine N-oxide
76786-86-2, 98302-76-2, 98302-77-3

(+)-chelidonine N-oxide

Conditions
ConditionsYield
With 3-chloro-benzenecarboperoxoic acid In chloroform for 0.666667h; Ambient temperature;A 14.5%
B 83%
With 3-chloro-benzenecarboperoxoic acid In chloroform for 1h; Ambient temperature;A 14.5%
B 83%
4-chloro-benzoyl chloride
122-01-0

4-chloro-benzoyl chloride

chelidonine
476-32-4

chelidonine

O-(4-chlorobenzoyl) chelidonine

O-(4-chlorobenzoyl) chelidonine

Conditions
ConditionsYield
With pyridine In dichloromethane81%
isobutyl chloroformate
543-27-1

isobutyl chloroformate

chelidonine
476-32-4

chelidonine

O-isobutoxycarbonyl chelidonine

O-isobutoxycarbonyl chelidonine

Conditions
ConditionsYield
With pyridine In dichloromethane at 20℃; for 10h;78.1%
benzyl chloroformate
501-53-1

benzyl chloroformate

chelidonine
476-32-4

chelidonine

C28H25NO7

C28H25NO7

Conditions
ConditionsYield
With pyridine In chloroform at 20℃;77.3%
benzoyl chloride
98-88-4

benzoyl chloride

chelidonine
476-32-4

chelidonine

C27H23NO6

C27H23NO6

Conditions
ConditionsYield
With pyridine In dichloromethane at 20℃; for 3h;71.1%
chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

chelidonine
476-32-4

chelidonine

C23H23NO7

C23H23NO7

Conditions
ConditionsYield
With pyridine In dichloromethane at 20℃; for 5h;70.5%
2-Chloronicotinoyl chloride
49609-84-9

2-Chloronicotinoyl chloride

chelidonine
476-32-4

chelidonine

O-(2-chloronicotinoyl) chelidonine

O-(2-chloronicotinoyl) chelidonine

Conditions
ConditionsYield
With pyridine In chloroform67.2%
4-Chlorobutanoyl chloride
4635-59-0

4-Chlorobutanoyl chloride

chelidonine
476-32-4

chelidonine

O-(4-chlorobutyryl) chelidonine

O-(4-chlorobutyryl) chelidonine

Conditions
ConditionsYield
With pyridine In dichloromethane58.1%
n-hexadecanoyl chloride
112-67-4

n-hexadecanoyl chloride

chelidonine
476-32-4

chelidonine

O-palmitoyl chelidonine

O-palmitoyl chelidonine

Conditions
ConditionsYield
With pyridine In chloroform50.8%
1-Bromopentane
110-53-2

1-Bromopentane

chelidonine
476-32-4

chelidonine

O-(n-pentyl) chelidonine

O-(n-pentyl) chelidonine

Conditions
ConditionsYield
With sodium hydride50.4%
p-toluenesulfonyl chloride
98-59-9

p-toluenesulfonyl chloride

chelidonine
476-32-4

chelidonine

O-(p-toluenesulfonyl) chelidonine

O-(p-toluenesulfonyl) chelidonine

Conditions
ConditionsYield
With pyridine In chloroform at 20℃; for 10h;50%
C18H22N2O9S
1186196-67-7

C18H22N2O9S

chelidonine
476-32-4

chelidonine

4-((6-((4-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-4-oxobutanoyl)oxy)hexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-((6-((4-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-4-oxobutanoyl)oxy)hexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;47%
4-nitro-benzoyl chloride
122-04-3

4-nitro-benzoyl chloride

chelidonine
476-32-4

chelidonine

C27H22N2O8

C27H22N2O8

Conditions
ConditionsYield
With pyridine In dichloromethane at 20℃;46%
4-(2-(2-((3-carboxypropanoyl)oxy)ethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide
1186196-66-6

4-(2-(2-((3-carboxypropanoyl)oxy)ethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide

chelidonine
476-32-4

chelidonine

4-(2-(2-((4-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-4-oxobutanoyl)oxy)ethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-(2-(2-((4-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-4-oxobutanoyl)oxy)ethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;46%
4-(2-(3-carboxypropanamido)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide

4-(2-(3-carboxypropanamido)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide

chelidonine
476-32-4

chelidonine

4-(2-(4-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-4-oxobutanamido)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-(2-(4-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-4-oxobutanamido)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;45%
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 8h;45%
C17H20N2O9S
1393477-78-5

C17H20N2O9S

chelidonine
476-32-4

chelidonine

4-(4-((5-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-5-oxopentanoyl)oxy)butoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-(4-((5-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-5-oxopentanoyl)oxy)butoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;45%
C17H16N2O9S

C17H16N2O9S

chelidonine
476-32-4

chelidonine

4-((4-((5-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-5-oxopentanoyl)oxy)but-2-yn-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-((4-((5-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-5-oxopentanoyl)oxy)but-2-yn-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;44%
C15H17N3O8S

C15H17N3O8S

chelidonine
476-32-4

chelidonine

4-(2-(5-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-5-oxopentanamido)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-(2-(5-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-5-oxopentanamido)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;43%
C16H19N3O8S

C16H19N3O8S

chelidonine
476-32-4

chelidonine

4-(3-(5-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-5-oxopentanamido)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-(3-(5-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-5-oxopentanamido)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;41%
C15H17N3O8S

C15H17N3O8S

chelidonine
476-32-4

chelidonine

4-((1-(4-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-4-oxobutanamido)propan-2-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-((1-(4-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-4-oxobutanamido)propan-2-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;38%
4-(4-((3-carboxypropanoyl)oxy)n-propoxy)-3-benzenesulfonyl-1,2,5-oxadiazole-2-oxide
1393477-75-2

4-(4-((3-carboxypropanoyl)oxy)n-propoxy)-3-benzenesulfonyl-1,2,5-oxadiazole-2-oxide

chelidonine
476-32-4

chelidonine

4-(3-((4-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-4-oxobutanoyl)oxy)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-(3-((4-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-4-oxobutanoyl)oxy)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;38%
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 10h;38%
1-iodo-butane
542-69-8

1-iodo-butane

chelidonine
476-32-4

chelidonine

C24H27NO5

C24H27NO5

Conditions
ConditionsYield
With sodium hydride In N,N-dimethyl-formamide at 60℃; for 10h;36.5%
C16H18N2O9S
1393477-77-4

C16H18N2O9S

chelidonine
476-32-4

chelidonine

4-(3-((5-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-5-oxopentanoyl)oxy)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-(3-((5-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-5-oxopentanoyl)oxy)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;36%
C19H24N2O9S

C19H24N2O9S

chelidonine
476-32-4

chelidonine

4-((6-((5-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-5-oxopentanoyl)oxy)hexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-((6-((5-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-5-oxopentanoyl)oxy)hexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;35%
4-(3-(3-carboxypropanamido)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide

4-(3-(3-carboxypropanamido)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide

chelidonine
476-32-4

chelidonine

4-(3-(4-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-4-oxobutanamido)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-(3-(4-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-4-oxobutanamido)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;34%
C17H20N2O10S

C17H20N2O10S

chelidonine
476-32-4

chelidonine

4-(2-(2-((5-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-5-oxopentanoyl)oxy)ethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-(2-(2-((5-(((6S)-13-methyl-5b,6,7,12b,13,14-hexahydro[1,3]dioxolo[4’,5’:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-yl)oxy)-5-oxopentanoyl)oxy)ethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;33%

476-32-4Relevant articles and documents

-

Benn,Mitchell

, p. 3701 (1969)

-

Enantioselective synthesis of chelidonine, a B/C-cis-11- hydroxyhexahydrobenzo[c]phenanthridine alkaloid

Ito, Miki,Konno, Fujiko,Kumamoto, Takuya,Suzuki, Noriyuki,Kawahata, Masatoshi,Yamaguchi, Kentaro,Ishikawa, Tsutomu

experimental part, p. 8041 - 8049 (2011/11/12)

Both enantiomers of chelidonine, a B/C-cis-11-hydroxyhexahydrobenzo[c] phenanthridine alkaloid, were synthesized by manipulation of the B/C-dehydro ring juncture of benzo[c]phenanthridine skeleton using Sharpless asymmetric dihydroxylation and stereospecific catalytic hydrogenation after introduction of oxygen functions on the C ring as key reaction steps for the construction of stereogenic centers.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 476-32-4